ARIAD Announces Support of Patients with Resistant or Intolerant CML Through Its Donation to Chronic Disease Fund

  ARIAD Announces Support of Patients with Resistant or Intolerant CML Through
  Its Donation to Chronic Disease Fund

Business Wire

CAMBRIDGE, Mass. -- April 2, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it had made a
donation to the Chronic Disease Fund (CDF) in support of patients with chronic
myeloid leukemia (CML) who are resistant or intolerant to prior therapy. CDF
is an independent non-profit charitable organization that helps eligible
patients with chronic diseases, cancer and other life-altering conditions
obtain the life-saving medications they need. Through ARIAD’s contribution,
the organization will provide financial assistance to eligible patients with
resistant or intolerant CML who require help paying their out-of-pocket
expenses, including co-pays or co-insurance. CDF will determine the
distribution of these funds and patient eligibility.

“Approximately 5,000 new cases of CML are diagnosed each year in the United
States, and over time, many of these patients will develop resistance or
intolerance to tyrosine kinase inhibitors,” said Marty Duvall, senior vice
president, commercial operations at ARIAD. “ARIAD is dedicated to helping
these refractory or intolerant patients receive the medications they need, and
we are proud to support the CDF as it assists patients.”

In addition, ARIAD has a patient assistance and support program designed to
help healthcare professionals or patients access, afford and adhere to
treatment. Information on the ARIAD PASS™ program for patient assistance is
available by calling 1-855-447-PASS (855-447-7277) or visiting
www.ARIADPASS.com.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and
Lausanne, Switzerland, is an integrated global oncology company focused on
transforming the lives of cancer patients with breakthrough medicines. ARIAD
is working on new medicines to advance the treatment of various forms of
chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer medicines.
For additional information, visit http://www.ariad.comor follow ARIAD on
Twitter (@ARIADPharm).

Contact:

ARIAD Pharmaceuticals, Inc.
For Investors:
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media:
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
 
Press spacebar to pause and continue. Press esc to stop.